The initiation of T-cell–mediated antitumor immune responses requires the uptake and processing of tumor antigens by dendritic cells and their presentation on MHC-I molecules. Here we show in a ...

Tumor-infiltrating lymphocytes (TIL) were presumed to be enriched for T cells recognizing specific tumor-rejection antigens and as originally envisioned by Rosenberg et al, 9 could potentially be ...

Immunologists have long searched for tumor-rejection antigens: molecules on tumor cells, but not on normal tissues, that could be recognized by the immune system and would lead the immune system to ...

Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res. 1997;3:2191-2196. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN.

In some cases, the identification of tumor-derived epitopes recognized by cytotoxic T lymphocytes led to the identification of specific tumor-rejection antigens.

Some examples are vaccines against breast cancer (the HER2 antigen), 82–84 B-cell lymphoma (the tumor immunoglobulin idiotype), 85 lung cancer (the MUC1 antigen), 86 melanoma (dendritic cells ...

Tumor infiltrating lymphocyte (TIL) therapy for cancer treatment, illustration. During TIL therapy, T-cells (blue) that recognize tumor cells (red) are obtained from a patient.

Unique TAAs are tumor specific and are often involved in tumor rejection so that they have also been termed tumor-rejection antigens (TRAs).

New prospects to increase the efficacy (prevention of antigen escape) and safety (reduction of on-target and off-tumor activity) of CAR therapy include combinatorial targeting and Boolean logic ...

“In the omics era, we are finding new and attractive cancer vaccine targets, but in some patients we may not know what the most effective tumor rejection antigen is,” says James L. Gulley, M.D ...